Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Alpha Nuclide
Ningbo, Zhejiang, Chinaastathera.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Alpha Nuclide is a leading radiopharmaceutical CRDMO and isotope supplier focusing on targeted alpha therapies (TAT). It supports clinical development for partners like NAYA Therapeutics (NY-703) and has strategic manufacturing and distribution agreements with International Isotopes Inc. to provide astatine-211, actinium-225, and other isotopes globally.
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalTargeted Alpha Therapy
- Industry
- Contract Research Organization
02
Partnerships
International Isotopes Inc. (INIS)NAYA TherapeuticsAdvanced Cyclotron Systems Inc. (ACSI)Atley Solutions
Beyond the preview
Go deeper on Alpha Nuclide.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alpha Nuclide.